Quarterly Financial Results
Neuland Laboratories Q1 FY27 Results: Total Income Surges 116%, PAT Soars 975% on Strong CMS & GDS Growth
NSE
NEULANDLAB
BSE
524558
- Neuland Laboratories Limited reported an exceptional Q1 FY27 with total income rising 116.3% YoY to ₹650.1 crore, while EBITDA increased 448.2% to ₹231.1 crore. Profit after tax (PAT) surged 975% YoY to ₹147.4 crore, driven by strong performance across both the Custom Manufacturing Solutions (CMS) and Generic Drug Substances (GDS) businesses, along with robust contribution from commercial products.
PRICE-SENSITIVE TRIGGER
Event: Neuland Laboratories announced its financial results for the quarter ended June 30, 2026.
Type: Quarterly Financial Results
Impact: Positive
Immediate Effect: The company delivered record year-on-year growth across revenue, EBITDA, and profitability, supported by strong execution in both CMS and GDS businesses, healthy commercial product sales, and continued expansion of its project pipeline.
Metrics:
Key Financial Metrics:
- Total Income: ₹650.1 crore, up 116.3% YoY from ₹300.6 crore.
- EBITDA: ₹231.1 crore, up 448.2% YoY from ₹42.1 crore.
- EBITDA Margin: 35.5%, compared with 14.0% in Q1 FY26, an expansion of 2,150 basis points.
- Profit Before Tax (PBT): ₹197.5 crore, up 1,036.7% YoY.
- PBT Margin: 30.4%, compared with 5.8% in Q1 FY26.
- Profit After Tax (PAT): ₹147.4 crore, up 975.0% YoY from ₹13.7 crore.
- PAT Margin: 22.7%, compared with 4.6% in Q1 FY26.
- Earnings Per Share (EPS): ₹114.9, compared with ₹10.7 in Q1 FY26.
Highlight:
- Neuland Laboratories delivered outstanding Q1 FY27 results with total income more than doubling, EBITDA increasing over fourfold, and PAT rising nearly tenfold, supported by strong performance across its CMS and GDS businesses.
What Happened ?
- Neuland Laboratories reported a strong start to FY27 with broad-based growth across its business segments. Management stated that both the Custom Manufacturing Solutions (CMS) and Generic Drug Substances (GDS) businesses performed encouragingly during the quarter, while commercial products accounted for the majority of revenue. The company also highlighted strengthening customer engagement, a healthy pipeline of projects, and continued investments in capacity expansion to support long-term growth.
key details
Business & Operational Highlights:
- Total income increased 116.3% YoY to ₹650.1 crore.
- EBITDA rose 448.2% YoY, reflecting significant operating leverage.
- PAT surged 975% YoY to ₹147.4 crore.
- Both CMS and GDS businesses delivered encouraging performance.
- Commercial products contributed the majority of quarterly revenue.
- Customer engagement deepened with broader capability-led discussions beyond individual projects.
Pipeline & Capacity Expansion:
- Pipeline projects continue to progress positively.
- Customer discussions are becoming broader and more strategic.
- Focus remains on consistent execution and building long-term customer partnerships.
- Significant capital expenditure projects remain on schedule.
- Management expects investment intensity to increase further to capture emerging growth opportunities.
Note:
- Neuland currently serves customers in around 80 countries and continues expanding its capabilities in APIs, complex intermediates, and custom manufacturing solutions, supported by ongoing investments in manufacturing capacity and regulatory compliance.
Risk Analysis
Summary:
- Despite exceptional quarterly performance, future growth will depend on successful execution of pipeline projects, sustained demand for commercial products, timely completion of expansion projects, and continued customer conversions within the CMS business.
Key Risks:
- Commercial product revenues may fluctuate across quarters.
- Pipeline projects require successful execution and commercialization.
- Continued capital expenditure may temporarily increase investment intensity.
- Pharmaceutical demand and regulatory changes could influence future growth.
Worst Case:
- Any slowdown in customer project conversions, delays in commercial launches, or execution challenges in ongoing expansion projects could moderate earnings growth in future quarters.
Risk Level: Medium
Company Commentary
Management highlighted the following during the quarter:
Saharsh Davuluri, Chief Executive Officer and Managing Director, said Q1 FY27 performance was broadly in line with expectations, with encouraging contributions from both the CMS and GDS businesses. He noted that while commercial products accounted for most of the revenue, the company is witnessing exciting progress in its project pipeline and increasingly engaging with customers on broader capability-led discussions. He added that Neuland remains focused on consistent execution, building customer confidence, and strengthening long-term partnerships, while expecting investment intensity to increase further as opportunities expand.
Official Exchange Filing: Neuland Laboratories Limited
